We have located links that may give you full text access.
Metformin suppresses gastric cancer progression through calmodulin‑like protein 3 secreted from tumor‑associated fibroblasts.
Oncology Reports 2019 January
Gastric cancer is one of the most common malignant tumor types worldwide, with a high morbidity and associated mortality. The interaction between gastric cancer cells and their microenvironment has a significant role in their maintenance and progression. Gastric tumor‑associated fibroblasts (TAFs) are among the major regulators of the gastric cancer microenvironment. Metformin, a classical anti‑diabetic drug, is known to prevent cancer progression. However, the effect of metformin on gastric TAFs and TAF‑associated cancer progression has remained to be elucidated. In the present study, TAFs were isolated from gastric cancer patients, pre‑treated with metformin and then co‑cultured with gastric cancer cell lines. It was demonstrated that pre‑treatment with 200 µM metformin reduced the stimulatory effect of TAFs on the proliferation of gastric cancer cells in co‑culture, suggesting that metformin impairs the tumor‑promoting role of TAFs. Using tandem mass tags‑based quantitative proteomic analysis, it was identified that metformin significantly affected the secretion of 32 proteins (14 upregulated and 18 downregulated) in the culture medium of gastric TAFs. Among these proteins, calmodulin‑like protein 3 (Calml3) was 2.88‑fold upregulated in the culture medium of gastric TAFs after metformin treatment and a further experiment using recombinant Calml3 indicated its suppressive effect on the clonogenicity of gastric cancer cells. It was concluded that metformin suppresses gastric cancer through stimulating Calml3 secretion from TAFs, which represents a novel anticancer mechanism of metformin.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app